Top

Published in:

01-03-2019 | Original Article

Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma

Authors: C. L. Chiang, Mark K. H. Chan, Cynthia S. Y. Yeung, Connie H. M. Ho, Francis A. S. Lee, Venus W. Y. Lee, Frank C. S. Wong, Oliver Blanck

Published in: Strahlentherapie und Onkologie | Issue 3/2019

Abstract

Purpose

We retrospectively evaluated the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with trans-arterial chemoembolization (TACE) as initial therapy in Barcelona Clinic Liver Cancer (BCLC) system stage B–C hepatocellular carcinoma (HCC).

Patients and methods

Seventy-two patients received a single dose of TACE followed by SBRT 4 weeks later. All patients had tumor sizes ≥5 cm, at least 700 ml of disease-free liver, Child–Pugh (CP) score ≤ B7 and tumor nodules ≤5. SBRT dose, ranging from 6 × 5–8 Gy or 5–10 × 4 Gy, was individualized according to normal tissue constraints. No subsequent scheduled treatment was delivered unless disease progression was observed. Local control (LC), overall survival (OS), progression-free survival (PFS), response rate (RR), and toxicity were evaluated.

Results

The patients’ characteristics were: median age 60 years (range 28–87 years); CP score A/B (n = 68/4); BCLC stage B/C (n = 51/21); solitary/multifocal (n = 37/35); portal vein invasion (n = 18). The median tumor size and GTV were 11.2 cm (range 5.0–23.6 cm) and 751 cm³ (range 41–4009 cm³), respectively. The median equivalent dose in 2 Gy per fraction (EQD2, α/β = 10) was 37.3 Gy2 (range, 28–72 Gy2). The median follow-up time was 16.8 months (range, 3–96 months). The objective RR was 68% and the 1‑year LC rate was 93.6% (95% CI, 87.6–100%). The median OS was 19.8 months (95% CI, 11.6–30.6 months). SBRT-related grade 3 or higher adverse gastrointestinal events and treatment-related death occurred in three (2.8%) and one patient (1.4%) respectively. No patient developed classical radiation-induced liver injury.

Conclusion

Our experience suggests that combined TACE and SBRT can be a safe and effective initial therapy for BCLC stage B–C HCC with appropriate patient selection. Further prospective trials are warranted.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Ca Cancer J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107 CrossRefPubMed

Llovet JM, Brú C, Bruix J (1999) Prognosis of Hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19(03):329–338. https://doi.org/10.1055/s-2007-1007122 CrossRefPubMed

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: An update. Hepatology 53(3):1020–1022. https://doi.org/10.1002/hep.24199 CrossRefPubMedPubMedCentral

El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576. https://doi.org/10.1053/j.gastro.2007.04.061 CrossRefPubMed

Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127(5, Supplement 1):S35–S50. https://doi.org/10.1053/j.gastro.2004.09.014 CrossRefPubMed

Yau T, Tang VYF, Yao T‑J, Fan S‑T, Lo C‑M, Poon RTP (2014) Development of Hongkong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(7):1691–1700. https://doi.org/10.1053/j.gastro.2014.02.032 CrossRefPubMed

Ng J, Wu J (2012) Hepatitis B‑ and hepatitis C‑related hepatocellular carcinomas in the United States: Similarities and differences. Hepat Mon 12(10 HCC):e7635. https://doi.org/10.5812/hepatmon.7635 CrossRefPubMedPubMedCentral

Omata M, Lesmana LA, Tateishi R, Chen P‑J, Lin S‑M, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RTP, Shiina S, Cheng AL, Jia J‑D, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4(2):439–474. https://doi.org/10.1007/s12072-010-9165-7 CrossRefPubMedPubMedCentral

Lo C‑M, Ngan H, Tso W‑K, Liu C‑L, Lam C‑M, Poon RT-P, Fan S‑T, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164–1171. https://doi.org/10.1053/jhep.2002.33156 CrossRefPubMed

10.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359(9319):1734–1739. https://doi.org/10.1016/s0140-6736(02)08649-x CrossRefPubMed

11.

Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT (2005) Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189–1196. https://doi.org/10.1111/j.1478-3231.2005.01170.x CrossRefPubMed

12.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J‑F, de Oliveira AC, Santoro A, Raoul J‑L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J‑F, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857 CrossRefPubMed

13.

Cheng A‑L, Kang Y‑K, Chen Z, Tsao C‑J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T‑S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. https://doi.org/10.1016/s1470-2045(08)70285-7 CrossRefPubMed

14.

Chan SL, Mo FKF, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BBY, Leung TWT, Lai PBS, Chan ATC, Mok TSK, Yeo W (2011) Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 26(2):340–347. https://doi.org/10.1111/j.1440-1746.2010.06329.x CrossRefPubMed

15.

Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26(4):657–664. https://doi.org/10.1200/jco.2007.14.3529 CrossRefPubMed

16.

Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639. https://doi.org/10.1200/jco.2012.44.1659 CrossRefPubMed

17.

Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881. https://doi.org/10.1007/s00066-014-0714-1 CrossRefPubMed

18.

Wong VYW, Tung SY, Ng AWY, Li FAS, Leung JOY (2010) Real-time monitoring and control on deep inspiration breath-hold for lung cancer radiotherapy—Combination of ABC and external marker tracking. Med Phys 37(9):4673–4683. https://doi.org/10.1118/1.3476463 CrossRefPubMed

19.

Wolthaus JWH, Sonke J‑J, van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EMF (2008) Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 70(4):1229–1238. https://doi.org/10.1016/j.ijrobp.2007.11.042 CrossRefPubMed

20.

Chan M, Chiang CL, Lee V, Cheung S, Leung R, Wong M, Lee F, Blanck O (2017) Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas. PLoS ONE 12(4):e174929. https://doi.org/10.1371/journal.pone.0174929 CrossRefPubMedPubMedCentral

21.

Chan MKH, Lee V, Chiang CL, Lee FAS, Law G, Sin NY, Siu KL, Wong FCS, Tung SY, Luk H, Blanck O (2016) Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas. Strahlenther Onkol 192(2):92–101. https://doi.org/10.1007/s00066-015-0929-9 CrossRefPubMed

22.

Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, Imajo K, Aoki Y, Saito H, Kunieda E (2016) Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 122(13):2041–2049. https://doi.org/10.1002/cncr.30008 CrossRefPubMed

23.

Honda Y, Kimura T, Aikata H, Nakahara T, Naeshiro N, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Ishikawa M, Kakizawa H, Kenjo M, Awai K, Nagata Y, Chayama K (2014) Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatogastroenterology 61(129):31–36PubMed

24.

Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, Yang E, Zarzour J, Bolus D, Smith JK, Gray S, White J, Eckhoff DE, DuBay DA (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm. HPB (Oxford) 17(2):140–149. https://doi.org/10.1111/hpb.12331 CrossRef

25.

Su T‑S, Lu H‑Z, Cheng T, Zhou Y, Huang Y, Gao Y‑C, Tang M‑Y, Jiang H‑Y, Lian Z‑P, Hou E‑C, Liang P (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma 〉5 cm. BMC Cancer 16:834. https://doi.org/10.1186/s12885-016-2894-9 CrossRefPubMedPubMedCentral

26.

Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M (2015) Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7(16):2009–2019. https://doi.org/10.4254/wjh.v7.i16.2009 CrossRefPubMedPubMedCentral

27.

Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J Hepatol 57(6):1258–1267. https://doi.org/10.1016/j.jhep.2012.07.025 CrossRefPubMed

28.

Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement. HPB (Oxford) 12(5):313–320. https://doi.org/10.1111/j.1477-2574.2010.00183.x CrossRef

29.

Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J‑FH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64(1):106–116. https://doi.org/10.1002/hep.28453 CrossRefPubMed

30.

Huo Y, Eslick GD (2015) Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis. Jama Oncol 1(6):756–765. https://doi.org/10.1001/jamaoncol.2015.2189 CrossRefPubMed

31.

Hong TS (2013) Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: Ready for prime time? J Clin Oncol 31(13):1619–1620. https://doi.org/10.1200/jco.2012.48.2703 CrossRefPubMed

32.

Chow PKH, Gandhi M, Tan S‑B, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han H‑S, Bae S‑H, Yoon H‑K, Lee R‑C, Hung C‑F, Peng C‑Y, Liang P‑C, Bartlett A, Kok KYY, Thng C‑H, Low AS-C, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC, Asia-Pacific Hepatocellular Carcinoma Trials Group (2018) SIRveNIB: Selective internal radiation therapy versus Sorafenib in asia-pacific patients with Hepatocellular carcinoma. J Clin Oncol 36(19):1913–1921. https://doi.org/10.1200/jco.2017.76.0892 CrossRefPubMed

33.

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller F, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(6):1155–1163. https://doi.org/10.1053/j.gastro.2016.08.029 CrossRefPubMedPubMedCentral

34.

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64. https://doi.org/10.1053/j.gastro.2009.09.006 CrossRefPubMed

35.

Radiation Therapy Oncology Group (2012) RTOG 1112 protocol - RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA. https://www.rtog.org/Portals/0/RTOG%20Broadcasts/Attachments/1112_master_w_update_5.7.13.pdf

36.

Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA (2013) Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 31(31):3980–3986. https://doi.org/10.1200/jco.2013.49.9202 CrossRefPubMed

37.

Guha C, Kavanagh BD (2011) Hepatic radiation toxicity: Avoidance and amelioration. Semin Radiat Oncol 21(4):256–263. https://doi.org/10.1016/j.semradonc.2011.05.003 CrossRefPubMedPubMedCentral

38.

Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, Salleron J, Henrot P (2017) Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS ONE 12(4):e176118. https://doi.org/10.1371/journal.pone.0176118 CrossRefPubMedPubMedCentral

39.

Vincenzi B, Di Maio M, Silletta M, D’Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G (2015) Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS ONE 10(7):e133488. https://doi.org/10.1371/journal.pone.0133488 CrossRefPubMedPubMedCentral

40.

Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 17:1533033818790217. https://doi.org/10.1177/1533033818790217 CrossRefPubMedPubMedCentral

41.

Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A‑L, Brunner TB (2018) The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1256-0 CrossRefPubMed

Title: Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma
Authors: C. L. Chiang
Mark K. H. Chan
Cynthia S. Y. Yeung
Connie H. M. Ho
Francis A. S. Lee
Venus W. Y. Lee
Frank C. S. Wong
Oliver Blanck
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 3/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1391-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B–C hepatocellular carcinoma

Abstract

Purpose

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Biliary duct stenosis after image-guided high-dose-rate interstitial brachytherapy of central and hilar liver tumors

Reduzierte strahleninduzierte Hirnnekrose bei Patienten mit Nasopharynxkarzinom durch Bevacizumab-Monotherapie

Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries

Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients

Repeated SBRT for in- and out-of-field recurrences in the liver

Einfluss des operativen Zugangswegs auf die Prognose von Frauen mit frühem Zervixkarzinom